CVR number 38815407
Industry 46.4610 Wholesale of pharmaceutical goods

Welland Danmark ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  7.9% 4.7% 7.9% 9.0% 8.3%  
Credit score (0-100)  32 46 31 26 29  
Credit rating  BB BBB BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Net sales  0 0 0 0 0  
Gross profit  2,411 2,317 2,303 1,806 1,201  
EBITDA  -281 585 499 -106 21.1  
EBIT  -550 334 214 -342 21.1  
Pre-tax profit (PTP)  -638.4 245.2 165.2 -403.1 -157.3  
Net earnings  -500.3 188.6 126.7 -320.7 -133.8  
Pre-tax profit without non-rec. items  -638 245 165 -403 -157  
 
See the entire income statement

Balance sheet (kDKK) 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Tangible assets total  196 223 270 693 19.3  
Shareholders equity total  391 580 707 386 252  
Interest-bearing liabilities  1,636 1,499 83.2 1,583 1,263  
Balance sheet total (assets)  3,915 4,051 3,604 3,777 3,197  
Net Debt  1,636 1,499 82.6 1,533 1,263  
 
See the entire balance sheet

Volume 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  2,411 2,317 2,303 1,806 1,201  
Gross profit growth  6.5% -3.9% -0.6% -21.6% -33.5%  
Employees  0 0 0 0 1  
Employee growth %  -100.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  3,915 4,051 3,604 3,777 3,197  
Balance sheet change%  -10.0% 3.5% -11.0% 4.8% -15.3%  
Added value  -281.3 584.9 499.0 -57.2 21.1  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -614 -424 -438 87 -674  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 1.0 2.0 -1.0 1.0  

Profitability 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  -22.8% 14.4% 9.3% -18.9% 1.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -13.0% 8.8% 6.2% -9.3% 0.6%  
ROI %  -19.6% 16.4% 15.6% -24.5% 1.2%  
ROE %  -78.0% 38.9% 19.7% -58.7% -42.0%  

Solidity 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Equity ratio %  10.0% 14.3% 19.6% 10.2% 7.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -581.7% 256.2% 16.6% -1,445.1% 5,979.2%  
Gearing %  418.3% 258.5% 11.8% 410.3% 501.2%  
Net interest  0 0 0 0 0  
Financing costs %  5.1% 6.6% 9.0% 7.4% 12.5%  

Liquidity 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Quick Ratio  0.4 0.3 0.4 0.2 0.3  
Current Ratio  0.9 1.0 1.1 1.0 1.0  
Cash and cash equivalent  0.0 0.0 0.6 50.5 0.1  

Capital use efficiency 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -377.4 108.0 331.5 -130.8 129.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 21  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 21  
EBIT / employee  0 0 0 0 21  
Net earnings / employee  0 0 0 0 -134